XML 50 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss $ (26,932) $ (21,155) $ (14,794)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 1,902 1,033 435
Loss on property and equipment 85    1
Accretion of discount, amortization of premium and changes in accrued interest of marketable securities 1,282 154 17
Gain from sale of investments of available-for-sale marketable securities (727) (26) (3)
Stock-based compensation to employees, directors and non-employee consultants 5,851 2,799 4,927
Increase in OCS receivables (1,990) (70) (230)
Decrease (increase) in other accounts receivable (143) (233) 64
Decrease (increase) in prepaid expenses (108) (237) 269
Increase (decrease) in trade payables 1,257 1,335 (424)
Increase in other accounts payable and accrued expenses 902 1,556 958
Increase (decrease) in deferred revenues (379) (679) 4,284
Increase (decrease) in advance payment from United Therapeutics (146) (1,183) 1,576
Increase in interest receivable on short-term deposits (36) (140) (395)
Linkage differences and interest on short and long-term restricted lease deposit 12 (30) 35
Accrued severance pay, net 49 (11) 5
Net cash used in operating activities (19,121) (16,887) (3,275)
CASH FLOWS FROM INVESTING ACTIVITIES:      
Purchase of property and equipment (1,573) (4,309) (1,480)
Repayment of (Investment in) short-term deposits 7,421 (10,202) (21,031)
Investment in long-term deposits (3)    (1,125)
Repayment of long-term restricted deposit 122 869 6
Proceeds from sale of available-for-sale marketable securities 6,113 1,848 884
Proceeds from redemption of available-for-sale marketable securities 754 529 114
Investment in available-for-sale marketable securities (10,851) (8,534) (8,165)
Net cash provided by (used in) investing activities 1,983 (19,799) (30,797)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Issuance of common stock and warrants, net of issuance costs 10,644 34,106   
Exercise of warrants and options 1,980 2,198 632
Net cash provided by financing activities 12,624 36,304 632
Decrease in cash and cash equivalents (4,514) (382) (33,440)
Cash and cash equivalents at the beginning of the period 9,007 9,389 42,829
Cash and cash equivalents at the end of the period 4,493 9,007 9,389
Supplemental disclosure of cash flow activities:      
Taxes paid due to non-deductible expenses 48 18 14
Supplemental disclosure of non-cash activities:      
Purchase of property and equipment on credit 243 872 738
Issuance of shares in consideration of new facility construction    1,400 3,672
Other receivables resulting from issuance of shares       13
Issuance of common stock under CHA Agreement (Note 1d) $ 10,414